Dudediligence.

Omeros Corporation

OMERNASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$0.00Mar ’25$9.9MMar ’26$28.5MJun ’26
Net income, by quarter
−$32.2MSep ’24−$31.4MDec ’24−$33.5MMar ’25−$25.4MJun ’25−$30.9MSep ’25$86.5MDec ’25$56.1MMar ’26$13.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating income−$173.6M−$163.4M−$164.5M−$167.0M−$122.8M
Net income$194.2M$47.4M−$117.8M−$156.8M−$3.4M
Operating cash flow−$109.7M−$86.5M$74.7M−$148.8M−$116.1M
Free cash flow−$110.0M−$86.6M$74.3M−$149.0M−$116.2M
Cash$100.8M$11.0M$7.1M$3.4M$9.7M
Debt$313.5M$315.3M$213.2M$164.9M$87.9M
Shares outstanding62.6M62.8M61.1M58.0M71.7M